Sino Biopharmaceutical (HKG:1177) has obtained marketing approval for its eribulin mesilate injection from China's National Medical Products Administration, a Wednesday bourse filing said.
The drug is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have received at least two chemotherapeutic regimens, according to the pharmaceutical company.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments